Pancreatic Cancer Research

ResearcherHirosaki UniversityActive in the last 2 years

Hayato Nagase

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5075017273. Sources: OpenAlex.

Their work

Papers
12
Trials
0
Grants
0
Labs led
0
Collaborators
19
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: none · 2019: 2 papers · 2020: none · 2021: 2 papers · 2022: 1 paper · 2023: none · 2024: 2 papers · 2025: none · 2026: 3 papers

Papers 12

  1. Neoadjuvant chemotherapy remodels the three-dimensional vascular architecture and immune microenvironment in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.humpath.2026.106238↗
  2. Limited Survival Benefit of Short-Course Neoadjuvant Gemcitabine Plus Nab-Paclitaxel for Resectable Pancreatic Cancer: A Prospective Phase II Study With a Prop… Co-author DOI 10.1016/j.jss.2026.08.063↗
  3. Prognostic Utility of the Cachexia Index in Resectable and Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Chemotherapy. Co-author DOI 10.1097/mpa.0000000000002706↗
  4. Noninvasive Computed Tomography-Based Deep Learning Model Predicts In Vitro Chemosensitivity Assay Results in Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000002270↗
  5. Postoperative long‑term outcomes of acute normovolemic hemodilution in pancreatic cancer: A propensity score matching analysis. Co-author DOI 10.3892/ol.2024.14369↗
  6. ASO Author Reflections: Reconsidering the Treatment Strategy for Resectable Pancreatic Cancer Using a Biomarker-Based Scoring System for Prediction of Early Re… Co-author DOI 10.1245/s10434-021-10920-3↗
  7. Eukaryotic initiation factor 2 signaling behind neural invasion linked with lymphatic and vascular invasion in pancreatic cancer. Co-author DOI 10.1038/s41598-021-00727-3↗
  8. Intraoperative Allogeneic Red Blood Cell Transfusion Negatively Influences Prognosis After Radical Surgery for Pancreatic Cancer: A Propensity Score Matching A… Co-author DOI 10.1097/mpa.0000000000001913↗
  9. Increase of Tumor Infiltrating γδ T-cells in Pancreatic Ductal Adenocarcinoma Through Remodeling of the Extracellular Matrix by a Hyaluronan Synthesis Suppress… Co-author DOI 10.1097/mpa.0000000000001211↗
  10. [A Case of Non-Resectable Pancreatic Cancer with Multiple Hepatic Metastases Treated with FOLFIRINOX Therapy and Conversion Surgery]. Co-author PMID 32156995↗
  11. 4-Methylumbelliferone Suppresses Hyaluronan Synthesis and Tumor Progression in SCID Mice Intra-abdominally Inoculated With Pancreatic Cancer Cells. Co-author DOI 10.1097/mpa.0000000000000741↗
  12. Antitumor effects of the hyaluronan inhibitor 4-methylumbelliferone on pancreatic cancer. Co-author DOI 10.3892/ol.2016.4930↗

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kenichi Hakamada · 12 shared papers, 2016–2026 · strength 2.06
  2. Keinosuke Ishido · 9 shared papers, 2019–2026 · strength 1.83
  3. Taiichi Wakiya · 6 shared papers, 2021–2026 · strength 1.12
  4. Yusuke Wakasa · 3 shared papers, 2026 · strength 0.93
  5. Satoru Tsuruta · 3 shared papers, 2026 · strength 0.93
  6. Taishu Kanda · 5 shared papers, 2021–2024 · strength 0.81
  7. Eri Yoshida · 4 shared papers, 2016–2024 · strength 0.43
  8. Tadashi Yoshizawa · 2 shared papers, 2021–2026 · strength 0.38
  9. Hiroshi Kijima · 2 shared papers, 2021–2026 · strength 0.38
  10. Kenta Ogasawara · 1 shared paper, 2026 · strength 0.26
  11. Yoshiki Nishiyama · 1 shared paper, 2026 · strength 0.26
  12. Shintaro Goto · 1 shared paper, 2026 · strength 0.26
  13. Daisuke Kudo · 3 shared papers, 2016–2019 · strength 0.23
  14. Akiko Suto · 2 shared papers, 2017–2019 · strength 0.17
  15. Yutaro Hara · 1 shared paper, 2022 · strength 0.16
  16. Takanobu Akaishi · 1 shared paper, 2019 · strength 0.09
  17. Atsushi Satō · 1 shared paper, 2019 · strength 0.09
  18. Takenori Takahata · 1 shared paper, 2019 · strength 0.09
  19. Tadashi Odagiri · 1 shared paper, 2019 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.